Local excision versus radical surgery for anal squamous cell carcinoma : a multicenter study in Japan
© 2024. The Author(s)..
BACKGROUND: The standard treatment for anal squamous cell carcinoma is chemoradiation therapy (CRT), but there is a possibility of over-treatment for early-stage disease. cTisN0 and cT1N0 disease is currently indicated for local excision, but it is unclear whether the indication of local excision can be expanded to cT2N0 disease.
METHODS: 126 patients with cTis-T2N0 anal cancer treated at 47 centers in Japan between 1991 and 2015 were included. Patients were first classified into the CRT group and surgical therapy group according to the initial therapy, and the latter was further divided into local excision (LE) and radical surgery (RS) groups. We compared prognoses among the groups, and analyzed risk factors for recurrence after local excision.
RESULTS: The CRT group (n = 87) and surgical therapy group (n = 39) showed no difference in relapse-free survival (p = 0.29) and overall survival (p = 0.94). Relapse-free survival curves in the LE (n = 23) and RS groups (n = 16) overlapped for the initial 3 years, but the curve for the LE group went lower beyond (p = 0.33). By contrast, there was no difference in overall survival between the two groups (p = 0.98). In the LE group, the majority of recurrences distributed in locoregional areas, which could be managed by salvage treatments. Muscular invasion was associated with recurrence after local excision (hazard ratio: 22.91, p = 0.011).
CONCLUSION: LE may be applied to selected patients with anal cancer of cTis-T2N0 stage. Given the high risk of recurrence in cases with muscular invasion, it may be important to consider close surveillance and additional treatment in such patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
International journal of clinical oncology - (2024) vom: 25. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Murai, Shin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 25.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s10147-024-02498-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370161890 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370161890 | ||
| 003 | DE-627 | ||
| 005 | 20240327000411.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10147-024-02498-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1349.xml |
| 035 | |a (DE-627)NLM370161890 | ||
| 035 | |a (NLM)38526623 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Murai, Shin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Local excision versus radical surgery for anal squamous cell carcinoma |b a multicenter study in Japan |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: The standard treatment for anal squamous cell carcinoma is chemoradiation therapy (CRT), but there is a possibility of over-treatment for early-stage disease. cTisN0 and cT1N0 disease is currently indicated for local excision, but it is unclear whether the indication of local excision can be expanded to cT2N0 disease | ||
| 520 | |a METHODS: 126 patients with cTis-T2N0 anal cancer treated at 47 centers in Japan between 1991 and 2015 were included. Patients were first classified into the CRT group and surgical therapy group according to the initial therapy, and the latter was further divided into local excision (LE) and radical surgery (RS) groups. We compared prognoses among the groups, and analyzed risk factors for recurrence after local excision | ||
| 520 | |a RESULTS: The CRT group (n = 87) and surgical therapy group (n = 39) showed no difference in relapse-free survival (p = 0.29) and overall survival (p = 0.94). Relapse-free survival curves in the LE (n = 23) and RS groups (n = 16) overlapped for the initial 3 years, but the curve for the LE group went lower beyond (p = 0.33). By contrast, there was no difference in overall survival between the two groups (p = 0.98). In the LE group, the majority of recurrences distributed in locoregional areas, which could be managed by salvage treatments. Muscular invasion was associated with recurrence after local excision (hazard ratio: 22.91, p = 0.011) | ||
| 520 | |a CONCLUSION: LE may be applied to selected patients with anal cancer of cTis-T2N0 stage. Given the high risk of recurrence in cases with muscular invasion, it may be important to consider close surveillance and additional treatment in such patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anal cancer | |
| 650 | 4 | |a Local excision | |
| 650 | 4 | |a Radical surgery | |
| 700 | 1 | |a Nozawa, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Yamada, Kazutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Saiki, Yasumitsu |e verfasserin |4 aut | |
| 700 | 1 | |a Sasaki, Kazuhito |e verfasserin |4 aut | |
| 700 | 1 | |a Murono, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Emoto, Shigenobu |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuzaki, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Yokoyama, Yuichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Abe, Shinya |e verfasserin |4 aut | |
| 700 | 1 | |a Nagai, Yuzo |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshioka, Yuichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Shinagawa, Takahide |e verfasserin |4 aut | |
| 700 | 1 | |a Sonoda, Hirofumi |e verfasserin |4 aut | |
| 700 | 1 | |a Sugihara, Kenichi |e verfasserin |4 aut | |
| 700 | 1 | |a Ajioka, Yoichi |e verfasserin |4 aut | |
| 700 | 1 | |a Ishihara, Soichiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of clinical oncology |d 1997 |g (2024) vom: 25. März |w (DE-627)NLM095566163 |x 1437-7772 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:25 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10147-024-02498-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 25 |c 03 | ||